HomeGeneticsConditionPrimary coenzyme Q10 deficiency
Back to Condition
Primary coenzyme Q10 deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Primary coenzyme Q10 deficiency

Primary coenzyme Q10 deficiency is a disorder involving a shortage of coenzyme Q10, which can severely affect the brain, muscles, and kidneys.

Overview

Primary coenzyme Q10 deficiency is a disorder that can affect many parts of the body, especially the brain, muscles, and kidneys. The severity and age of onset vary widely, ranging from life-threatening infantile encephalomyopathy to adult-onset ataxia.

Symptoms

  • Neurological: Ataxia (coordination and balance issues), seizures, intellectual disability, hypotonia, dystonia, spasticity, nystagmus, vision loss, and sensorineural hearing loss.
  • Kidney:Nephrotic syndrome, which can lead to proteinuria, hypercholesterolemia, ascites, swelling, hematuria, and potentially irreversible end-stage renal disease.
  • Heart: A type of heart disease that enlarges and weakens the heart muscle (cardiomyopathy).

Causes

The condition is caused by mutations in COQ genes (such as COQ2, COQ4, COQ6, COQ8A, and COQ8B), which are involved in the synthesis of coenzyme Q10. Coenzyme Q10 is essential for energy production (oxidative phosphorylation), pyrimidine synthesis, and acting as an antioxidant. A deficiency impairs these processes, causing cells to malfunction.

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of a gene in each cell have mutations.

Frequently Asked Questions

Genetic confirmation of pathogenic COQ gene mutations or documented low tissue CoQ10 levels justifies trial of oral CoQ10 (ubiquinone) at 15‑30 mg/kg/day, with close monitoring of neurologic, cardiac, and renal parameters for improvement.
Increasing proteinuria, rising serum creatinine, new‑onset hypertension, swelling of the legs, or persistent hypercholesterolemia despite optimal CoQ10 dosing suggest renal decline and warrant nephrology referral for possible adjunctive therapies or dialysis planning.
Yes, adults with confirmed COQ mutations may experience modest gait and fatigue improvement; typical dosing ranges from 300 mg to 1,200 mg daily divided doses, titrated based on tolerance and serum CoQ10 levels.
Look for unexplained hypotonia, seizures, or poor feeding combined with signs of kidney involvement such as proteinuria or edema, and consider metabolic work‑up including plasma and urinary CoQ10 levels when these features appear together.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA